

GenCore version 5.1.4_p5-4578
Copyright (c) 1993 - 2003 Compugen Ltd.

OM protein - protein search, using sw model

Run on: April 23, 2003, 12:53:20 ; Search time 40 Seconds
(without alignments)
1938.797 Million cell updates/sec

Title: US-09-635-949-34

Perfect score: 3289

Sequence: 1 MDLFLALVSSLVLAQAAE.....TGEIGLDDVSLKHCSEER 582

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 908470 seqs, 133250620 residues

Total number of hits satisfying chosen parameters: 908470

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : A_Geneseq.101002.*

1: /SID52/qcqdta/geneseq/geneseqp-emb1/AA1980.DAT.*
2: /SID52/qcqdta/geneseq/geneseqp-emb1/AA1981.DAT.*
3: /SID52/qcqdta/geneseq/geneseqp-emb1/AA1982.DAT.*
4: /SID52/qcqdta/geneseq/geneseqp-emb1/AA1983.DAT.*
5: /SID52/qcqdta/geneseq/geneseqp-emb1/AA1984.DAT.*
6: /SID52/qcqdta/geneseq/geneseqp-emb1/AA1985.DAT.*
7: /SID52/qcqdta/geneseq/geneseqp-emb1/AA1986.DAT.*
8: /SID52/qcqdta/geneseq/geneseqp-emb1/AA1987.DAT.*
9: /SID52/qcqdta/geneseq/geneseqp-emb1/AA1988.DAT.*
10: /SID52/qcqdta/geneseq/geneseqp-emb1/AA1989.DAT.*
11: /SID52/qcqdta/geneseq/geneseqp-emb1/AA1990.DAT.*
12: /SID52/qcqdta/geneseq/geneseqp-emb1/AA1991.DAT.*
13: /SID52/qcqdta/geneseq/geneseqp-emb1/AA1992.DAT.*
14: /SID52/qcqdta/geneseq/geneseqp-emb1/AA1993.DAT.*
15: /SID52/qcqdta/geneseq/geneseqp-emb1/AA1994.DAT.*
16: /SID52/qcqdta/geneseq/geneseqp-emb1/AA1995.DAT.*
17: /SID52/qcqdta/geneseq/geneseqp-emb1/AA1996.DAT.*
18: /SID52/qcqdta/geneseq/geneseqp-emb1/AA1997.DAT.*
19: /SID52/qcqdta/geneseq/geneseqp-emb1/AA1998.DAT.*
20: /SID52/qcqdta/geneseq/geneseqp-emb1/AA1999.DAT.*
21: /SID52/qcqdta/geneseq/geneseqp-emb1/AA2000.DAT.*
22: /SID52/qcqdta/geneseq/geneseqp-emb1/AA2001.DAT.*
23: /SID52/qcqdta/geneseq/geneseqp-emb1/AA2002.DAT.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	3289	100.0	582	22	Human PRO17 protei
2	3097.5	94.2	546	22	Clone 16467945.0.8
3	2820	85.7	509	20	Amino acid sequenc
4	2820	85.7	509	22	Human PRO polypept
5	2820	85.7	509	22	Human PRO334 prote
6	1096	33.3	554	22	Human polypeptide
7	1096	33.3	554	22	Human EXMAD-2 SEQ
8	1096	33.3	554	23	Human EGF motif-co
9	1092.5	33.2	553	23	Human EGF motif-co
10	1091.5	33.2	553	21	Human TANGO 212.

11	1091.5	33.2	553	22	AA093622	Human polypeptide,
12	1091.5	33.2	553	23	AA015368	Human EGF motif-co
13	1091.5	33.2	554	23	AA015370	Human EGF motif-co
14	1091.5	33.2	559	23	AA015369	Human EGF motif-co
15	1084	33.0	573	22	AA040942	Human polypeptide
16	1076.5	32.7	553	20	AAV18108	protein encoded by
17	1068.5	32.5	551	23	AB072294	kat protein isolat
18	1051.5	32.0	183	21	AA042085	Human ORFX ORF1849
19	1041.5	31.7	502	23	AA015367	Human EGF motif-co
20	1041.5	31.7	537	23	AA015360	Human EGF motif-co
21	1039.5	31.6	537	20	AAV18110	Protein encoded by
22	1027.5	31.2	211	22	AA004843	Human polypeptide
23	879.5	26.7	331	22	AA023677	Human EGF encoded
24	879.5	26.7	338	20	AAV1702	Human PRO320 prote
25	879.5	26.7	338	21	AA044258	Human PRO320 (UNQ2
26	879.5	26.7	338	21	AA018669	Amino acid sequenc
27	879.5	26.7	338	21	AAV95339	Human PRO320 antit
28	873.5	26.6	333	21	AA014129	Murine TANGO 212.
29	845.5	25.7	284	21	AAV76110	Kat TGP-beta homol
30	845.5	25.7	284	22	AA056049	Skin cell protein,
31	845.5	25.7	284	23	ABB72249	Rat protein isolat
32	644.5	19.6	251	22	ABB10214	Human cDNA SEQ ID
33	644.5	19.6	251	22	AA016935	Human novel secret
34	594	18.1	164	23	AA015364	Human EGF motif-co
35	592.5	18.0	123	22	AA070546	Human PRO16 protei
36	516	15.7	94	21	AA042082	Human ORFX ORF1846
37	409.5	12.5	100	20	AAV18109	EGF motif.I containi
38	409.5	12.5	100	23	AA015359	Human EGF motif-co
39	407	12.4	2809	23	AA066169	Human fibrillin 3
40	404	12.3	87	22	AA070548	Clone 16467945.0.8
41	402	12.2	333	21	AAV84709	Amino acid sequenc
42	397.5	12.1	2912	22	ARG06402	Novel human diagno
43	393.5	12.0	1118	22	AA050209	Human fibrillin-11
44	381.5	11.6	576	22	AA080174	Human protein SEQ
45	381.5	11.6	576	22	AA080175	Human protein SEQ

ALIGNMENTS

RESULT 1

AA070547
ID AA070547 standard; Protein; 582 AA.

XX AA070547;

XX AC AA070547;

XX DT 09-MAY-2001 (first entry)

XX DE Human PRO17 protein sequence SEQ ID NO:34.

XX KW Human; PRO; PROX; cytostatic; immunomodulatory; reproduction;

XX KW gene therapy; cell proliferation; differentiation disorder; cancer;

XX KW immune associated disorder; gestational disease; pre-clampsia.

XX OS Homo sapiens.

XX PN WO200110902-A2.

XX PD 15-FEB-2001.

XX PF 11-AUG-2000; 2000WO-US21857.

XX PR 11-AUG-1999; 99US-0148433.

XX PR 10-AUG-2000; 2000US-0148433.

XX PA (CUKA-) CUNAGHN CORP.

XX PI Shimkets RA, Fernandes E;

XX DR WPI; 2001-147509/15.

XX DR N-PSDB; AAF74448.

XX PT Nucleic acids encoding secreted polypeptides, designated PROX

Db 284 PPIINRPTSKPTTRTPKPTPIPTPPPPPLPTLPTLPTTTPPTTGLTTIAPAS 343
 QY 380 TTPGGITVDNRVQTDQPKRGDVFIPROPNDLFEIPIERGVSAADDEAKDDPGVLVHSC 439
 Db 344 TTPGGITVDNRVQTDQPKRGDVFIPROPNDLFEIPIERGVSAADDEAKDDPGVLVHSC 403
 QY 440 NFDKGLCGWIREKNDLHWEPIRDPAGGQYLTVSAKAPGGKAARLVLPGLRLHSGDLG 499
 Db 404 NFDHGLCGWIREKNDLHWEPIRDPAGGQYLTVSAKAPGGKAARLVLPGLRLHSGDLG 463
 QY 500 LSFHRKVTGLHSCTIQVFKRKAHCAALWGRNGGHWROQTITLRGADIKSVVFKGPKR 559
 Db 464 LSFHRKVTGLHSSTLQVFKRKAHCAALWGRNGGHWROQTITLRGADIKSVVFKGPKR 523
 QY 560 RGHTRIGLDDVSLAKKGCSRRK 582
 Db 524 RGHTRIGLDDVSLAKKGCSRRK 546

RESULT 3
 AAY13397
 ID AAY13397 standard; Protein: 509 AA.
 XX
 AC AAY13397;
 XX
 DT 25-JUN-1999 (first entry)
 XX
 DE Amino acid sequence of protein PRO334.
 XX
 KW Secreted protein; transmembrane protein; human; enterocolitis;
 KW Zollinger-Ellison syndrome; gastrointestinal ulceration;
 KW congenital microvillus atrophy; skin disease; cell growth;
 KW abnormal keratinocyte differentiation; psoriasis; epithelial cancer;
 KW Parkinson's disease; Alzheimer's disease; ALS; neuropathy;
 KW fibromodulin; dermal scarring; Usher Syndrome; Atrophia areata;
 KW anti-thrombotic; wound healing; tissue repair.
 XX
 OS Homo sapiens.
 XX
 PN WO9914128-A2.
 XX
 PD 25-MAR-1999.
 XX
 PF 16-SEP-1998; 98WO-US19330.
 XX
 PR 25-NOV-1997; 97US-0066840.
 PR 17-SEP-1997; 97US-0059113.
 PR 17-SEP-1997; 97US-0059115.
 PR 17-SEP-1997; 97US-0059117.
 PR 17-SEP-1997; 97US-0059119.
 PR 17-SEP-1997; 97US-0059121.
 PR 17-SEP-1997; 97US-0059122.
 PR 18-SEP-1997; 97US-0059184.
 PR 18-SEP-1997; 97US-0059263.
 PR 15-OCT-1997; 97US-0059266.
 PR 17-OCT-1997; 97US-0062125.
 PR 17-OCT-1997; 97US-0062285.
 PR 17-OCT-1997; 97US-0062287.
 PR 24-OCT-1997; 97US-0063486.
 PR 24-OCT-1997; 97US-0062814.
 PR 24-OCT-1997; 97US-0062816.
 PR 24-OCT-1997; 97US-0063045.
 PR 24-OCT-1997; 97US-0063120.
 PR 24-OCT-1997; 97US-0063121.
 PR 24-OCT-1997; 97US-0063127.
 PR 24-OCT-1997; 97US-0063128.
 PR 27-OCT-1997; 97US-0063329.
 PR 27-OCT-1997; 97US-0063327.
 PR 28-OCT-1997; 97US-0063541.
 PR 28-OCT-1997; 97US-0063542.
 PR 28-OCT-1997; 97US-0063544.
 PR 28-OCT-1997; 97US-0063549.
 PR 28-OCT-1997; 97US-0063550.

PR 28-OCT-1997; 97US-0063564.
 PR 29-OCT-1997; 97US-0063435.
 PR 29-OCT-1997; 97US-0063704.
 PR 29-OCT-1997; 97US-0063732.
 PR 29-OCT-1997; 97US-0063738.
 PR 29-OCT-1997; 97US-0063734.
 PR 29-OCT-1997; 97US-0064215.
 PR 29-OCT-1997; 97US-0063735.
 PR 31-OCT-1997; 97US-0063870.
 PR 31-OCT-1997; 97US-0064103.
 PR 03-NOV-1997; 97US-0064248.
 PR 07-NOV-1997; 97US-0064809.
 PR 12-NOV-1997; 97US-0065186.
 PR 17-NOV-1997; 97US-0065846.
 PR 18-NOV-1997; 97US-0065693.
 PR 21-NOV-1997; 97US-0066120.
 PR 21-NOV-1997; 97US-0066364.
 PR 24-NOV-1997; 97US-0066772.
 PR 24-NOV-1997; 97US-0066466.
 PR 24-NOV-1997; 97US-0066770.
 PR 24-NOV-1997; 97US-0066511.
 PR 24-NOV-1997; 97US-0066453.
 XX
 PA (GETH) GENENTECH INC.
 XX
 PI Chen J., Goddard A., Gurney AL, Pennica D, Wood WI, Yuan J;
 XX
 DR WPI; 1999-229533/19.
 DR N-PSDB; AAX52268.
 XX
 PT New isolated human genes and polypeptides used in, e.g. treatment of
 PT gastrointestinal ulceration
 PS
 XX Claim 12; Fig 110; 320pp; English.
 CC
 CC AAY13344-403 represent secreted and transmembrane human proteins.
 CC The cDNA sequences are obtained from cDNA libraries, prepared from
 CC fetal lung, fetal kidney, fetal brain, fetal liver and fetal retina.
 CC The encoded polypeptides have specific uses based on their homology to
 CC known polypeptides, e.g. PRO211 and PRO217 can be used for disorders
 CC associated with the preservation and maintenance of gastrointestinal
 CC mucosa and the repair of acute and chronic mucosal lesions
 CC (e.g. enterocolitis, Zollinger-Ellison syndrome, gastrointestinal
 CC ulceration and congenital microvillus atrophy), skin diseases associated
 CC with abnormal keratinocyte differentiation (e.g. psoriasis, epithelial
 CC cancers such as lung squamous cell carcinoma of the vulva and gliomas),
 CC potent effects on cell growth and development, discases related to
 CC growth or survival of nerve cells including Parkinson's disease,
 CC Alzheimer's disease, ALS, neuropathies or cancer. PRO265 can be used as
 CC for fibromodulin, e.g. for reducing dermal scarring. PRO264 can be used
 CC as a target for anti-tumor drugs. PRO533 may be used in the treatment
 CC of Usher Syndrome or Atrophia areata; PRO269 can be used as an
 CC anti-thrombotic agent; PRO287 polypeptides and portions may have
 CC therapeutic applications in wound healing and tissue repair; PRO317 can
 CC be used for treating problems of the kidney, uterus, endometrium, blood
 CC vessels, or related tissue, e.g. in the heart of genital tract.
 XX
 SQ Sequence 509 AA;
 Query Match 85.7%; Score 2820; DB 20; Length 509;
 Best Local Similarity 90.9%; Pred. No. 9.8e-164;
 Matches 501; Conservative 0; Mismatches 4; Indels 46; Gaps 2;
 QY 1 MDFLLALVLVSSLYLQAAAEFDGRWPROIVSSIGLCRYGGRIDCCGWAROSWGQCPFY 60
 Db 1 MDFLLALVLVSSLYLQAAAEFDGRWPROIVSSIGLCRYGGRIDCCGWAROSWGQCP-- 58
 QY 61 VLQRRIARICQLKAVCPCKHGECIGENKCKCHPGYAGKTCIQVLNECGLKPRCKHR 120
 Db 59 -----VCQPRCKHGFCIGPNKCKCHPGYAGKTCNODLNECGLKPRCKHR 103
 QY 121 CMNTYGSYKCYCLNGYMLMDPGCSSSALTCSMANCYQCDVVYKGIQRCQSPGQLAPD 180

Db 104 CMNTYGSYKCYCLNGYMIHPDGSSEALTCSEMANCOYGCIDVVKVGQIRQCQPSFGLHLPD 163
 QY 181 GRTCDVDDECATGRASCPREFRCQVNTFGSYICKIKGFDLMYIGGKYQCHIDEC:SLGY 240
 Db 164 GRTCDVDDECATGRASCPREFRCQVNTFGSYICKIKGFDLMYIGGKYQCHIDEC:SLGY 223
 QY 241 QCSSEFARCYNVRSYKCKEGYQCHIDEC:VYIPKVMIEPSGP IHPKNGTILKGDTCN 300
 Db 224 QCSSEFARCYNVRSYKCKEGYQCHIDEC:VYIPKVMIEPSGP IHPKNGTILKGDTCN 283
 QY 301 NNWIPDVGSTWPPKTPYIPPIITNRPSTKPTRTPKTPPTPTPPPPPLTELTPLP 360
 Db 284 NNWIPDVGSTWPPKTPYIPPIITNRPSTKPTRTPKTPPTPTPPPPPLTELTPLP 343
 QY 361 PTPPERTGLTTIAPAASTPPGGITVDNRVQTDPOKPRGDFVIFRQPSNDLFEIFEIER 420
 Db 344 PTPPERTGLTTIAPAASTPPGGITVDNRVQTDPOKPRGDFVIFRQPSNDLFEIFEIER 386
 QY 421 GVSADDEAKDDPGVIVHSCNFDHGLCCWIREKINDIHWEPTRDPAAGGYLTIVSAKAPGG 480
 Db 387 GVSADDEAKDDPGVIVHSCNFDHGLCCWIREKINDIHWEPTRDPAAGGYLTIVSAKAPGG 434
 QY 481 KAARVLPLGRMLMISGDLCLSPRIKVTGLISGTLQVFPVVKHGAALWGRNGGHWROT 540
 Db 435 KAARVLPLGRMLMISGDLCLSPRIKVTGLISGTLQVFPVVKHGAALWGRNGGHWROT 494
 QY 541 QITLGRADIKS 551
 Db 495 QITLGRADIKS 505

RESULT 4
 AAU29049
 ID AAU29049 standard; Protein; 509 AA.
 XX AAU29049;
 AC AAU29049;
 DT 18-DEC-2001 (first entry)
 XX Human PRO polypeptide sequence #26.
 DE
 XX PRO polypeptide; mammal; tumour; cancer; human; cattle; horse; sheep;
 KW dog; cat; pig; goat; rabbit; tumour necrosis factor alpha; TNF-alpha;
 KW blood; chondrocyte cell; cell proliferation; cell differentiation; colon;
 KW adrenal; lung; breast; prostate; rectum; cervix; liver; genetic disorder.
 XX Homo sapiens.
 OS
 XX WO200168848-A2.
 PN
 XX 20-SEP-2001.
 PD
 XX
 XX 28-FEB-2001; 2001WO-US06520.
 PF
 XX
 PR 01-MAR-2000; 2000WO-US05601.
 PR 02-MAR-2000; 2000WO-US05841.
 PR 03-MAR-2000; 2000US-187202P.
 PR 06-MAR-2000; 2000US-186968P.
 PR 14-MAR-2000; 2000US-189320P.
 PR 14-MAR-2000; 2000US-189328P.
 PR 15-MAR-2000; 2000WO-US06884.
 PR 21-MAR-2000; 2000US-190828P.
 PR 21-MAR-2000; 2000US-191007P.
 PR 21-MAR-2000; 2000US-191048P.
 PR 21-MAR-2000; 2000US-191314P.
 PR 28-MAR-2000; 2000US-192655P.
 PR 29-MAR-2000; 2000US-193032P.
 PR 29-MAR-2000; 2000US-193053P.
 PR 30-MAR-2000; 2000WO-US08439.
 PR 04-APR-2000; 2000US-194449P.
 PR 04-APR-2000; 2000US-194647P.
 PR 11-APR-2000; 2000US-195975P.
 PR 11-APR-2000; 2000US-196000P.

PR 11-APR-2000; 2000US-196187P.
 PR 11-APR-2000; 2000US-196690P.
 PR 11-APR-2000; 2000US-196820P.
 PR 18-APR-2000; 2000US-198121P.
 PR 18-APR-2000; 2000US-198585P.
 PR 25-APR-2000; 2000US-199397P.
 PR 25-APR-2000; 2000US-199550P.
 PR 25-APR-2000; 2000US-199654P.
 PR 03-MAY-2000; 2000US-201516P.
 PR 17-MAY-2000; 2000WO-US13705.
 PR 22-MAY-2000; 2000WO-US14042.
 PR 30-MAY-2000; 2000WO-US14941.
 PR 02-JUN-2000; 2000WO-US15264.
 PR 05-JUN-2000; 2000US-209832P.
 PR 28-JUL-2000; 2000WO-US20710.
 PR 22-AUG-2000; 2000US-0644848.
 PR 24-AUG-2000; 2000WO-US23328.
 PR 08-NOV-2000; 2000WO-US30952.
 PR 01-DEC-2000; 2000WO-US42678.
 PR 20-DEC-2000; 2000WO-US34956.
 XX (GETH) GENENTECH INC.
 PA Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
 XX Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
 PI WPI: 2001-602746/68.
 DR N-PSDB: AAS45950.
 DR
 DR
 XX Novel nucleic acids encoding PRO polypeptides, used to diagnose the
 PT presence of tumours, such as prostate and breast tumours, in mammals and
 PT to screen for modulators of the compounds -
 PT
 XX Claim 11: Fig 52: 774pp: English.
 PS
 XX Sequences AAU29024-AAU29328 represent PRO polypeptides of the invention.
 CC The PRO polypeptides and their associated nucleic acids can be used to
 CC detect the presence of a tumour in a mammal by comparing the level of
 CC expression of a PRO polypeptide in a test sample of cells from the animal
 CC and a control sample of normal cells, whereby a higher level of
 CC expression in the test sample indicates the presence of a tumour in the
 CC mammal. Mammals include dogs, cats, cattle, horses, sheep, pigs, goats
 CC and rabbits but are preferably human. The polypeptides can be used to
 CC stimulate tumour necrosis factor (TNF) alpha release from human blood,
 CC when contacted with it. A specific polypeptide can be used to stimulate
 CC the proliferation or differentiation of chondrocyte cells. The PRO
 CC proteins can be used to determine the presence of tumours and also
 CC susceptibility to tumour development, particularly adrenal, lung, colon,
 CC breast, prostate, rectal, cervical, or liver tumours, in mammalian
 CC subjects. The oligonucleotide probes specific for the PRO nucleic acids
 CC can be used for genetic analysis of individuals with genetic disorders.
 XX
 SQ Sequence 509 AA:

Query Match 85.7% Score 2820; DH 22: Length 509;
 Best Local Similarity 90.9% Pred. No. 9,8e-164;
 Matches 501; Conservative 0; Mismatches 4; Indels 46; Gaps 2;
 QY 1 MDTLLALVLVSSLYLOAAAEFDGRPRQIVSSIGLCRYGRIDCGWAWROSWSGQUPFY 60
 Db 1 MDTLLALVLVSSLYLOAAAEFDGRPRQIVSSIGLCRYGRIDCGWAWROSWSGQUP 58
 QY 61 VLQRQIARIIRCULKAVCPCKKHGEFIGPNKCKHPGAGKTCIGVLFNFCGLKHPKPKR 120
 Db 59 -----VCQPRCKHGEFIGPNKCKHPGAGKTCIGVLFNFCGLKHPKPKR 104
 QY 121 CMNTYGSYKCYCLNGYMIHPDGSSEALTCSEMANCOYGCIDVVKVGQIRQCQPSFGLHLP 180
 Db 104 CMNTYGSYKCYCLNGYMIHPDGSSEALTCSEMANCOYGCIDVVKVGQIRQCQPSFGLHLP 164
 QY 181 GRTCDVDDECATGRASCPREFRCQVNTFGSYICKIKGFDLMYIGGKYQCHIDEC:SLGY 240
 Db 164 GRTCDVDDECATGRASCPREFRCQVNTFGSYICKIKGFDLMYIGGKYQCHIDEC:SLGY 224

QY 241 QCSFARCYNVRGSKCKEKGQDGLTCVYIPKVMIEPSGPIHVPKNGTILKGDGTN 300
DB 224 QCSFARCYNVRGSKCKEKGQDGLTCVYIPKVMIEPSGPIHVPKNGTILKGDGTN 283
QY 301 NNWIPDVGSTWMPKTPYIPPIITNRPTSKPTTRPTKPTPIPTPPPPPLTELRTPLP 360
DB 284 NNWIPDVGSTWMPKTPYIPPIITNRPTSKPTTRPTKPTPIPTPPPPPLTELRTPLP 343
QY 361 PTTPERPTTGLTTIAPAASTPPGGITVDNRVQTDPOKPRGDFVIPRQPSNDLFEIFEIER 420
DB 344 PTTPERPTTGLTTIAPAASTPPGGITVDNRVQTDPOKPRGDFV----- 386
QY 421 GVSADDEAKDDPGVLVHSCNFDHGLCGWIREKNDLHWEPIRDPAGQYLTVSAAKAPGG 480
DB 387 -----SVLVHSCNFDHGLCGWIREKNDLHWEPIRDPAGQYLTVSAAKAPGG 434
QY 481 KAARLVLPGLRLMHSGLDCLSFPRKVTGLHSGTLOVFRKHGAAGALWGRNGHGWROT 540
DB 435 KAARLVLPGLRLMHSGLDCLSFPRKVTGLHSGTLOVFRKHGAAGALWGRNGHGWROT 494
QY 541 QITLRGADIKS 551
DB 495 QITLRGADIKS 505

RESULT 5
AAH80265
ID AAH80265 standard; Protein; 509 AA.

AC AAB80265;
XX 24-APR-2001 (first entry)
XX Human PRO334 protein.

XX Human; PRO: dermatological; antipsoriatic; cytostatic; antiinflammatory;
KW antiaparkinsonian nootropic; neuroprotective; vulnerary; cardiant;
KW antiangiogenic; vasotropic; antiasthmatic; antirheumatic; cancer;
KW antiarthritic; antinfertility; antidiabetic; antiviral; diabetes;
KW ophthalmological; gene therapy; skin disease; gastrointestinal disorder;
KW ischaemia; inflammation.

XX Homo sapiens.

XX WO200104311-A1.

XX 18-JAN-2001.

XX 22-FEB-2000; 2000WO-0504414.

XX 07-JUL-1999; 99US-0143048.
XX 26-JUL-1999; 99US-0145698.
XX 28-JUL-1999; 99US-0146222.
XX 08-SEP-1999; 99WO-US20594.
XX 13-SEP-1999; 99WO-US20944.
XX 15-SEP-1999; 99WO-US21090.
XX 15-SEP-1999; 99WO-US21547.
XX 05-OCT-1999; 99WO-US23089.
XX 29-NOV-1999; 99WO-US28214.
XX 30-NOV-1999; 99WO-US28313.
XX 16-DEC-1999; 99WO-US30095.
XX 20-DEC-1999; 99WO-US30911.
XX 20-DEC-1999; 99WO-US30999.
XX 05-JAN-2000; 99WO-US00219.

XX (GETH) GENENTECH INC.

XX Ashkenazi AJ, Hotstein D, Desnoyers L, Eaton DL, Ferrara N;
PI Flivaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;
PI Godowski PJ, Grimaldi CJ, Curney AL, Hillan KJ, Kljavin LJ;
PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;
PI Williams PM, Wood WI;

XX

DR WPI: 2001-081051/09.
DR N-PSDB; AAF72426.

XX Sixty one nucleic acids encoding PRO polypeptides which are useful in
PT the treatment of skin diseases (e.g. psoriasis), cancers (e.g. lung
PT squamous cell carcinoma) and neurodegenerative diseases (e.g.
PT Alzheimer's disease) -

XX Claim 1; Fig 110; 393pp; English.

XX The present sequence is one of sixty one novel secreted and
CC transmembrane PRO polypeptides. The PRO polypeptides are
CC useful for treating skin diseases (e.g. psoriasis), cancers (e.g. lung
CC squamous cell carcinoma), gastrointestinal disorders (e.g.
CC enterocolitis), neurodegenerative diseases (e.g. Alzheimer's disease,
CC parkinson's disease), wound repair, cardiovascular disorders (e.g.
CC endometrial bleeding angiogenesis, ischaemias such as coronary
CC ischaemia, atherosclerosis), inflammatory disorders (e.g. asthma,
CC rheumatoid arthritis, multiple sclerosis), infertility, AIDS and
CC diabetes and retinal disorders such as retinitis pigmentosum.
CC The PRO nucleic acids have applications in molecular biology, including
CC use as hybridization probes, and in chromosome and gene mapping.

XX Sequence 509 AA;

Query Match 85.7%; Score 2820; DB 22; Length 509;
Best Local Similarity 90.9%; Pred. No. 9.8e-164;
Matches 501; Conservative 0; Mismatches 4; Indels 46; Gaps 2;

QY 1 MDFLLALVLVSSLYLQAAAEFDGRWPRQIVSSIGLCRYGGRIDCCGWARQSWGQCQOPY 60

DB 1 MDFLLALVLVSSLYLQAAAEFDGRWPRQIVSSIGLCRYGGRIDCCGWARQSWGQCQ-- 58

QY 61 VLQRRTARIKQQLKAVCPKCKHGCIGPNKCKCHPCYACKTCTIOVNHCGCLKPRCKKRR 120

DB 59 -----VCQPRCKHGCIGPNKCKCHPCYACKTCTIOVNHCGCLKPRCKKRR 103

QY 121 CMNTYSKYCYCLNGYMLMPDSCSSALTCSMANCOYGDVVKGOIRCOCPSPHGLAPD 180

DB 104 CMNTYSKYCYCLNGYMLMPDSCSSALTCSMANCOYGDVVKGOIRCOCPSPHGLAPD 163

QY 181 GRTCDVDDECATGRASCPFRQCVNTFGSYICKCHKGFELMYIGGKYQCHDIDECSELQY 240

DB 164 GRTCDVDDECATGRASCPFRQCVNTFGSYICKCHKGFELMYIGGKYQCHDIDECSELQY 223

QY 241 QCSFARCYNVRGSKCKEKGQDGLTCVYIPKVMIEPSGPIHVPKNGTILKGDGTN 300

DB 224 QCSFARCYNVRGSKCKEKGQDGLTCVYIPKVMIEPSGPIHVPKNGTILKGDGTN 283

QY 301 NNWIPDVGSTWMPKTPYIPPIITNRPTSKPTTRPTKPTPIPTPPPPPLTELRTPLP 360

DB 284 NNWIPDVGSTWMPKTPYIPPIITNRPTSKPTTRPTKPTPIPTPPPPPLTELRTPLP 343

QY 361 PTTPERPTTGLTTIAPAASTPPGGITVDNRVQTDPOKPRGDFVIPRQPSNDLFEIFEIER 420

DB 344 PTTPERPTTGLTTIAPAASTPPGGITVDNRVQTDPOKPRGDFV----- 386

QY 421 GVSADDEAKDDPGVLVHSCNFDHGLCGWIREKNDLHWEPIRDPAGQYLTVSAAKAPGG 480

DB 387 -----SVLVHSCNFDHGLCGWIREKNDLHWEPIRDPAGQYLTVSAAKAPGG 434

QY 481 KAARLVLPGLRLMHSGLDCLSFPRKVTGLHSGTLOVFRKHGAAGALWGRNGHGWROT 540

DB 435 KAARLVLPGLRLMHSGLDCLSFPRKVTGLHSGTLOVFRKHGAAGALWGRNGHGWROT 494

QY 541 QITLRGADIKS 551

DB 495 QITLRGADIKS 505

RESULT 6
AAM39156

PT preventing disorders associated with expression of EXMAD such as
 XX proliferative, immune and genetic disorders -
 PS Claim 1: Page 88-89; 129pp; English.
 XX The present invention provides the protein and coding sequences for 25
 CC novel extracellular matrix and adhesion-associated proteins (EXMADS).
 CC These are designated EXMAD-1, EXMAD-2, EXMAD-3, EXMAD-4, EXMAD-5,
 CC EXMAD-6, EXMAD-7, EXMAD-8, EXMAD-9, EXMAD-10, EXMAD-11, EXMAD-12,
 CC EXMAD-13, EXMAD-14, EXMAD-15, EXMAD-16, EXMAD-17, EXMAD-18, EXMAD-19,
 CC EXMAD-20, EXMAD-21, EXMAD-22, EXMAD-23, EXMAD-24 and EXMAD-25. They are
 CC useful in the prevention and treatment of cancers, cell proliferation,
 CC cardiovascular, reproductive, immune, musculoskeletal, developmental and
 CC gastrointestinal disorders and inflammation.
 XX
 SQ Sequence 554 AA;
 Query Match 33.3%; Score 1096; DB 22; Length 554;
 Best Local Similarity 37.9%; Pred. No. 6.7e-59;
 Matches 217; Conservative 99; Mismatches 168; Indels 88; Gaps 15;
 QY 34 GLCRYGGRIDCCWGWARSQCCQPFYVLRQRIARICOLKAVQCPRCKHGECIGPNKCK 93
 Db 39 GVCHYGTKLACCYGNRRNSKGVCE-----ATCEPGCKFGEYGVNPKCR 81
 QY 94 CHPGYAGKTCIQVINECGLKPRCKHRCMNTYSGYKCYCLNGYMLMPDGSSSALTCMA 153
 Db 82 CFPYGTGKTCSDQVNECGMKPRCPQHRCVNTHGSKYKFCLSGHMLMPDATCVNSNTCAMI 141
 QY 154 NCQYGCDDVVKGIKCOCPSPGLQAPDGRGTCVDVDECATGRASCPRFCQVNTFGSYCK 213
 Db 142 NCQYSCDETEEGPQCLCPSSGLRLAPNGRDCLDIDECASGVKICPNYRRCVNTFGSYCK 201
 QY 214 CHKGFDLMYIGKYQCHDIDECSLQCYQSSPARCYNVRGSKYCKKGYQDGLTCVYI 273
 Db 202 CHIGFELQYISGRYDCIDINECTDMSHTCSHUANGCNFTQGSFKCKCKGYKGNLCSAI 261
 QY 274 PKVMIEPSGPIHVPKNGTILKGDGNNWIPDVGSTWMPKTPYIPILINRPTSKPTT 333
 Db 262 PENSVK-----EVLRAPGFI-----KDRIKLLAHKNSMKKKA 294
 QY 334 R---PTPKPTPTPTPPPPPLTELRLPTPTTPTPTTGLTTIAPAASTPPG----- 383
 Db 295 KIKNVTPEPTPTP-----KVNLPENYEE-----IVSRGSGHGGKKGNEEK 338
 QY 384 ---GITYDNKVO-----TDQPKRGDVPPIQPSNDLFEIPEIR-GVSADDEAKDDPG 433
 Db 339 MKEGLEDEKREKALKNDTEERSLRGDFVFPKVNAGEFGLLVQKALTSLEHKADLN 398
 QY 434 VLVHSCNFDHGLCGWIREKNDLHWEPT-RDPAGQYLTVSNKAPGKAARLVPLGLRL 492
 Db 399 ISV-DCSFNHGTCDMKQDREDDFDNPADRONAIGFYMAVPALAGHKKDDIGRLKLLLPOL 457
 QY 493 MUISGLCLSRFRKVTGLHSHTQVFRKHGHAALWGRNGHG--WROTOITL-RGAD- 548
 Db 458 QPQSNFCLLFYELAGDKVGKRLRVFK--NSNNALAWKTTISEDEKWKTKIQLYQGTDA 515
 QY 549 IKSVPKQKRRGHTGTEIGLDVSLKKGHCSE 580
 Db 516 KTSIIPEABERGKGTGEIADVGVLLVSLGLCPD 547
 RESULT 8
 ID AAO15371
 AC AAO15371 standard; protein; 554 AA.
 AC AAO15371;
 XX
 DT 19-SEP-2002 (first entry)
 DE Human bCF motif-containing protein, SEQ ID No 32.
 DE Human; epidermal growth factor motif; EGF motif; EGFL6;
 KW

KW epithelial tissue growth; tissue repair; tissue regeneration;
 KW corneal transplant healing; skin graft; wound healing; cancer; leukaemia;
 KW nervous system disorder; infection; autoimmune disorder; inflammation;
 KW multiple sclerosis; anaemia; periodontal disease; haemophilia;
 KW fertility enhancement.
 XX Homo sapiens.
 OS WO200230977-A2.
 PN 18-APR-2002.
 PD 15-OCT-2001; 2001WO-US32257.
 PF 13-OCT-2000; 2000US-0687860.
 PR (HYSE-) HYSEQ INC.
 PA Asundi V, Ford JE, Drmanac RT, Liu C, Yamasaki V, Yeung G;
 PI Tang TY, Zhang J, Zhou P, Zhou H;
 XX WPI; 2002-426270/45.
 DR N-PSDB; AAL43906.
 XX Novel isolated epidermal growth factor motif polypeptide, termed EGFL6,
 PT for treating cancer, nervous system disorders, immune deficiencies,
 PT autoimmune disorders, coagulation disorders and inflammatory conditions
 XX Claim 20: Page 181-183; 183pp; English.
 PS The invention comprises the amino acid and coding sequences of human
 CC epidermal growth factor (EGF) motif-containing proteins (EGFL6 proteins).
 CC The DNA and protein sequences of the invention are useful for inhibiting
 CC the proliferation of cells expressing an EGFL6 protein. The DNA and
 CC protein sequences of the invention are useful for stimulating epithelial
 CC tissue growth, for tissue repair and regeneration, corneal transplant
 CC healing, skin graft production and wound healing. The DNA and protein
 CC sequences are useful for treating cancer, leukaemia, nervous system
 CC disorders, infection, autoimmune disorders (e.g. multiple sclerosis),
 CC anaemia, periodontal diseases, haemophilia, inflammatory conditions, and
 CC for effecting bodily characteristics and fertility of male or female
 CC subjects. The present amino acid sequence represents a human EGF motif-
 CC containing protein.
 XX SQ Sequence 554 AA;
 Query Match 33.3%; Score 1096; DB 23; Length 554;
 Best Local Similarity 37.9%; Pred. No. 6.7e-59;
 Matches 217; Conservative 99; Mismatches 168; Indels 88; Gaps 15;
 QY 34 GLCRYGGRIDCCWGWARSQCCQPFYVLRQRIARICOLKAVQCPRCKHGECIGPNKCK 93
 Db 39 GVCHYGTKLACCYGNRRNSKGVCE-----ATCEPGCKFGEYGVNPKCR 81
 QY 94 CHPGYAGKTCIQVINECGLKPRCKHRCMNTYSGYKCYCLNGYMLMPDGSSSALTCMA 153
 Db 82 CFPYGTGKTCSDQVNECGMKPRCPQHRCVNTHGSKYKFCLSGHMLMPDATCVNSNTCAMI 141
 QY 154 NCQYGCDDVVKGIKCOCPSPGLQAPDGRGTCVDVDECATGRASCPRFCQVNTFGSYCK 213
 Db 142 NCQYSCDETEEGPQCLCPSSGLRLAPNGRDCLDIDECASGVKICPNYRRCVNTFGSYCK 201
 QY 214 CHKGFDLMYIGKYQCHDIDECSLQCYQSSPARCYNVRGSKYCKKGYQDGLTCVYI 273
 Db 202 CHIGFELQYISGRYDCIDINECTDMSHTCSHUANGCNFTQGSFKCKCKGYKGNLCSAI 261
 QY 274 PKVMIEPSGPIHVPKNGTILKGDGNNWIPDVGSTWMPKTPYIPILINRPTSKPTT 333
 Db 262 PENSVK-----EVLRAPGFI-----KDRIKLLAHKNSMKKKA 294
 QY 334 R---PTPKPTPTPTPPPPPLTELRLPTPTTPTPTTGLTTIAPAASTPPG----- 383
 Db 295 KIKNVTPEPTPTP-----KVNLPENYEE-----IVSRGSGHGGKKGNEEK 338
 QY 384 ---GITYDNKVO-----TDQPKRGDVPPIQPSNDLFEIPEIR-GVSADDEAKDDPG 433
 Db 339 MKEGLEDEKREKALKNDTEERSLRGDFVFPKVNAGEFGLLVQKALTSLEHKADLN 398
 QY 434 VLVHSCNFDHGLCGWIREKNDLHWEPT-RDPAGQYLTVSNKAPGKAARLVPLGLRL 492
 Db 399 ISV-DCSFNHGTCDMKQDREDDFDNPADRONAIGFYMAVPALAGHKKDDIGRLKLLLPOL 457
 QY 493 MUISGLCLSRFRKVTGLHSHTQVFRKHGHAALWGRNGHG--WROTOITL-RGAD- 548
 Db 458 QPQSNFCLLFYELAGDKVGKRLRVFK--NSNNALAWKTTISEDEKWKTKIQLYQGTDA 515
 QY 549 IKSVPKQKRRGHTGTEIGLDVSLKKGHCSE 580
 Db 516 KTSIIPEABERGKGTGEIADVGVLLVSLGLCPD 547

Db 295 KIKNVTPEPTPTTP-----KVNLOPPNYEE-----IVSRGSGSHOCKKGNREK 338
 QY 384 ---GITVDNRVQ-----TDQPKRGDVFIPROPSNDLFEIFEIER-GVSADDEAKDDPG 433
 Db 339 MKESLEDEKEEKALANDIEERSLRGDVFPKPVNEAGFGLILVQKALTSKLEHKADLN 398
 QY 434 VLVHSCNFDHGLCCWIREKINDLHWEP1-RDPAGGQYLTVSAAKANGGKAARLVLPGLRL 492
 Db 399 ISV-DCSFNIGICDWDKODREDDFNPAORDNAIGFYMAVPALAGHKKGIGRLKLLPDL 457
 QY 493 MHSQDCLSPRIUKVTGLHSQTLQVFRKUGAIGAALWGRNGHG--WROTQITL-RGAD- 548
 Db 458 OPOSNFCILFDYRLAGDKVCKLRVFK--NSNNALAWKTTSEDEKWKTKIQLVQCTDA 515
 QY 549 IKSVVFKGKRRGHTGEIGLDDVSLKKGHCSE 580
 Db 516 TKSIIFEAEERGKGTGEIAVDGVLVSLGLCPD 546
 RESULT 9
 AAO15361
 ID AAO15361 standard; Protein: 553 AA.
 AC AAO15361;
 XX 19-SEP-2002 (first entry)
 DE Human EGF motif-containing protein, SEQ ID NO 6.
 KW Human: epidermal growth factor motif; EGF motif; EGF16;
 KW epithelial tissue growth; tissue repair; tissue regeneration;
 KW corneal transplant healing; skin graft; wound healing; cancer; leukaemia;
 KW nervous system disorder; infection; autoimmune disorder; inflammation;
 KW multiple sclerosis; anaemia; periodontal disease; haemophilia;
 KW fertility enhancement.
 XX Homo sapiens.
 XX Key Location/Qualifiers
 FT Misc-difference 357
 FT /note- "Encoded by WTA"
 XX W0200230977-A2.
 XX 18-APR-2002.
 XX 15-OCT-2001; 2001W0-0532257.
 XX 13-OCT-2000; 2000US-0687860.
 XX (HYSE-) HYSEQ INC.
 XX Asundi V, Ford JE, Drmanac RT, Liu C, Yamasaki V, Yeung G;
 PI Tang TY, Zhang J, Zhou P, Zhou H;
 XX WPI: 2002-426270/45.
 DR N-PSDB: AAL43890.
 XX Novel isolated epidermal growth factor motif polypeptide, termed EGFL6,
 PT for treating cancer, nervous system disorders, immune deficiencies,
 PT autoimmune disorders, coagulation disorders and inflammatory conditions
 PT .
 XX Example 3; Fig 5; 183pp; English.
 PS The invention comprises the amino acid and coding sequences of human
 CC epidermal growth factor (EGF) motif-containing proteins (EGF16 proteins).
 CC The DNA and protein sequences of the invention are useful for inhibiting
 CC the proliferation of cells expressing an EGF16 protein. The DNA and
 CC protein sequences of the invention are useful for stimulating epithelial
 CC tissue growth, for tissue repair and regeneration, corneal transplant
 CC healing, skin graft production and wound healing. The DNA and protein
 CC sequences are useful for treating cancer, leukaemia, nervous system

CC disorders, infection, autoimmune disorders (e.g. multiple sclerosis),
 CC anaemia, periodontal diseases, haemophilia, inflammatory conditions, and
 CC for effecting bodily characteristics and fertility of male or female
 CC subjects. The present amino acid sequence represents a human EGF motif
 CC containing protein.
 XX Sequence 553 AA;
 SO Query Match 33.2%; Score 1092.5; Db 23; Length 553;
 Best Local Similarity 37.7%; Pred. No. 116 58;
 Matches 215; Conservative 96; Mismatches 174; Indels 87; Gaps 14;
 QY 34 GLCRYGGRIDCCWGAAROSWGOCQPPYVLORXRIARICLKAVCPGPKCKHCFICPNKCK 93
 Db 39 GVCHYGTKLACCYGWRNSKGVCE-----ATCEGCKFGEVCFNCKR 81
 QY 94 CHPGVAGKTCIOVLNECGDLKPRCKHRCNMNTYGYCYCLNGYMLMDGSSSSALTSMA 154
 Db 82 CPFGYTGKTCSDVNRHCGMKPRCQHRVNTGSGYKCFCLSGHMLMDATVNSRTCAI 141
 QY 154 NCQYGGDVVKGQIRCCPSPGLQAPDGRTCVDVDECATGRASCFPRFCVNTFGSYCK 214
 Db 142 NCQYSCEDTEEGPQCLCPSSGLRLAPNGECGLDIDECNSKXVICPNRRCVNTFGSYCK 201
 QY 214 CHKGFDIAYIGKYOCCHIDECISLGOYOCSPARCYNVHGSKYCKCKGYSQDGLTVYI 274
 Db 202 CHIGFELQVIGRYDCIDINECTMDSHITCSHHANGFNTGSGSKCKCKGKONGLECSAI 261
 QY 274 PKVMIEPSPGIHVPKNGTILKGDGTGNNNWIPDVGSTWMPPTPIPIPIITNRPTSKITT 433
 Db 262 PENSVK-----KVIKAPGFI-----KDRKKLKAHKNMKKKA 294
 QY 334 R---PTPKPTPTPTPPPPPLTELRTPLPTTPPTPTGLTTIAPAASTPPG----- 383
 Db 295 KIKNVTPEPTPTTP-----KVNLOPPNYE-----IVSRGSGSHCKKGNREK 433
 QY 384 ---GITVDNRVQ-----TDQPKRGDVFIPROPSNDLFEIFEIERGVSADDEAKDDPG 434
 Db 339 MKESLEDEKEEKALANDIEERSLRGDVFPKPVNEAGFGLILVQKALTSKLEHKADLN 398
 QY 435 LVHSCNFDHGLCCWIREKINDLHWEP1-RDPAGGQYLTVSAAKANGGKAARLVLPGLRL 492
 Db 399 ISV-DCSFNIGICDWDKODREDDFNPAORDNAIGFYMAVPALAGHKKGIGRLKLLPDL 457
 QY 494 MHSQDCLSPRIUKVTGLHSQTLQVFRKUGAIGAALWGRNGHG--WROTQITL-RGAD- 549
 Db 458 OPOSNFCILFDYRLAGDKVCKLRVFK--NSNNALAWKTTSEDEKWKTKIQLVQCTDA 515
 QY 550 KSVVFKGKRRGHTGEIGLDDVSLKKGHCSE 580
 Db 516 TKSIIFEAEERGKGTGEIAVDGVLVSLGLCPD 546
 RESULT 10
 AAO1423
 ID AAO1423 standard; Protein: 553 AA.
 AC AAO1423;
 XX 20-OCT-2000 (first entry)
 DE Human TANGO 212.
 KW TANGO; 128; 140; 197; 212; 213; 224; 239; modulating agent; asthma;
 KW graft versus-host diseases; rheumatoid arthritis; psoriasis;
 KW inflammatory bowel disease; septic shock; ulcerative colitis;
 KW Crohn's disease; chronic myelogenous leukemia; cancer; liver
 KW disease; Hodgkin's disease; osteoarthritis; Lyme's disease;
 KW cachexia; autoimmune disease; myasthenia gravis; autoimmune diabetes;
 KW systemic lupus erythematosus; transgenic animal; diagnosis;
 KW prognosis; prophylactic; therapeutic; human.
 XX Homo sapiens.

XX WO200039284-A1.
 XX 06-JUL-2000.
 XX 23-DEC-1999: 99WO-US31025.
 XX 30-DEC-1998: 98US-0223546.
 XX (MILL-) MILLENNIUM PHARM INC.
 XX Holtzman DA;
 XX WPI: 2000-465743/40.
 XX N-PSDB; AAA47456.
 PT Novel nucleic acid sequences encoding TANGO-128, 140, 197, 212, 213,
 PT 224 and 239 polypeptides useful for the treatment of asthma, rheumatoid
 PT arthritis, psoriasis and autoimmune diseases
 XX Claim 8; Fig 5; 209pp; English.
 XX Nucleic acids encoding TANGO polypeptides are useful as modulating
 CC agents for regulating cellular processes like asthma, graft
 CC versus-host diseases, rheumatoid arthritis, psoriasis, inflammatory
 CC bowel disease, septic shock, ulcerative colitis, Crohn's disease,
 CC chronic myelogenous leukemia, cancer, liver disease, Hodgkin's
 CC disease, osteoarthritis, Lyme's disease, cachexia and autoimmune
 CC diseases e.g. myasthenia gravis, autoimmune diabetes and systemic
 CC lupus erythematosus. The nucleic acids are also useful for producing
 CC transgenic animals and the TANGO polypeptides themselves. Partial
 CC TANGO-128, 140, 197, 212, 213, 224, 239 sequences are useful in
 CC forensic biology, for diagnostic assays, prognostic assays,
 CC pharmacogenomics and for monitoring clinical trials. TANGO
 CC polypeptides are suitable for both prophylactic and therapeutic
 CC methods for treating a subject at risk of a disorder or having a
 CC disorder associated with aberrant TANGO expression. A wide range
 CC of cellular disorders can be treated.
 XX Sequence 553 AA:
 SQ Query Match 33.2%; Score 1091.5; DH 21; Length 553;
 Best Local Similarity 37.7%; Pred. No. 1.2e-58;
 Matches 215; Conservative 96; Mismatches 173; Indels 87; Gaps 14;

QY 34 GLCRYGGRIDCCWGRARQSGWQCPFFVLRQRIARICOLKAVCPCKHGEICGPNCK 93
 DB 39 GVCHYGTKLACCYGWRNRNKGVE-----ATCEPGCKFGECVGNCK 81

QY 94 CHPCYACKTCIQVINECGIKPRCKHRCMTYGSYKCYCLNGYMLMPDSCSSALTCMA 153
 DB 82 CFPGYTGKTCQSDVNECGMKRPRCQHRVNTHGSYKCFCLSGHMLPDCATVNSRTCAMI 141

QY 154 NCOYGDVVKQIIRCCPQGLQIAPDGRITCVDDCATGRASCPFRVCNFTFGSYICK 213
 DB 142 NCOYSCDETEGQCLPSSGLAFAPNGRCLDIDBCASGKVICPNRRVCNFTFGSYICK 201

QY 214 CHGFDMYTGKYQCHDIDECSLGQYQSSFARCVNRGYSYKCKEGYQGDGLFCVYI 273
 DB 202 CHICFELQYISGRYDCIDINCKTMDSHRSHANCENTQGSFKCKQYKGNGLKCSAI 261

QY 274 PKVMIEPSCP IHPKNGNTILKQDTNNWIPVGGSTWPPKTPYPIITNRPSTSKPTT 333
 DB 262 PENSVK-----EVLRAFGTI-----KDRIKKLLAHKNSMKKA 294

QY 334 R---PTPKPTPIPTPPPPPLPTELRTPLPTTPPTTGLTTIAPAASTPPG----- 383
 DB 295 KIKNVTPETRTPTP-----KVNLPENYEE-----IVSGGNSHGKCKNEK 338

QY 384 ---GITVDNRVQ-----TDPQKRGDVFITPROPSNDLFEIFFEIRGVSADEAKDDPGV 434
 DB 339 MKGELEDEKREKALANDIEERSLRGDFVFPKVNEAGEFGLIIVQRKAITSKLEHRDLNI 398

QY 435 LVHSCNFDHGLCGWIREKXNDLHWEP I-RDPAGCOYLTVSAAKAPCGKAARLVIPIGRIM 493
 DB 399 SV-DCSENFHICIDWKQDRDEEDWNPADRDNAIGFYMAVPALAGHKDIGRLKLLPDLQ 457
 QY 494 HSGDCLSLFRHKVTGLHSGTGLQVFRKKGHAAGAALWGRNGHG--WROTQITL-RGAD-I 549
 DB 458 POSNFCILLFDYRLACDQKVKLRVFK--NSNNALAEKXTTSEDEKWKTKIQLYQGTDTAT 515
 QY 550 KSVFPGKGRRGHTGEIGLDDVSLRKKHCSE 580
 DB 516 KSIIFEAEERGKGTGEIAVDGVLVSLGLCPD 546

RESULT 11
 AAM93622
 ID AAM93622 standard; Protein: 553 AA.
 XX AC AAM93622;
 XX DT 06-NOV-2001 (first entry)
 XX Human polypeptide, SEQ ID NO: 3456.
 KW Human; full length cDNA; cDNA synthesis; oligo-capping.
 XX Homo sapiens.
 PN EP1130094-A2.
 PD 05-SEP-2001.
 PF 07-JUL-2000; 2000EP-0114089.
 PR 08-JUL-1999; 98JP-0194486.
 PR 11-JAN-2000; 2000JP-0118774.
 PR 02-MAY-2000; 2000JP-0183765.
 XX (HELI-) HELIX RES INST.
 PI Ota T, Nishikawa T, Isogai T, Hayashi K, Ishii S, Kawai Y;
 PI Wakamatsu A, Sugiyama T, Nagai K, Kojima S, Otsuki T, Koqa H;
 XX WPI: 2001-524255/58.
 DR N-PSDB; AAK94555.
 XX 830 Primers useful for synthesizing full length cDNA clones and their
 PT use in genetic manipulation.
 XX Claim 8; SEQ ID NO 3456; 1380pp + sequence listing; English.
 CC The invention relates to primers for synthesizing full length cDNA
 CC clones. 830 cDNA molecules encoding a human protein have been
 CC isolated and nucleotide sequences of 5' and 3' ends of the cDNA
 CC molecules have been determined. Primers for synthesizing the full length
 CC cDNA are useful for clarifying the function of the protein encoded by
 CC the cDNA. The full length clones were obtained by construction of full
 CC length enriched cDNA libraries that were synthesised by the oligo-capping
 CC method. The primers enable the production of the full length cDNA easily
 CC without any special methods. The present sequence is a polypeptide
 CC encoded by a full length human cDNA of the invention.
 CC Note: The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in CD-ROM format directly from EPO.
 XX Sequence 553 AA:

Query Match 33.2%; Score 1091.5; DH 22; Length 553;
 Best Local Similarity 37.7%; Pred. No. 1.2e-58;
 Matches 215; Conservative 96; Mismatches 173; Indels 87; Gaps 14;

QY 34 GLCRYGGRIDCCWGRARQSGWQCPFFVLRQRIARICOLKAVCPCKHGEICGPNCK 93
 DB 39 GVCHYGTKLACCYGWRNRNKGVE-----ATCEPGCKFGECVGNCK 81

QY 94 CHRYGAGKTCIQVLNEGLKPRCKXKRCNNTYGSYKCYCLNGYMLMPDSCSSALTCGSA 153
 DB 82 CFCYCTCKTCQVNVNCGMKPRICQRCVNTGHSYKFCPLISCHMLMPDTCVNSRTICAM 141
 QY 154 NCOYGVGVKQIKCOCPSPGQIAPIDRCVCVIVDRCATCRASCPFRPCVNTFGSYICK 213
 DB 142 NCOYSCDETEEGPQCLCPSSGLAPNGRDLIDECASGKVLCPYNRRCVNTFGSYICK 201
 QY 214 CHKGFILMYIGCKYQCHDIDECISIGQYQSSPARCYNVNGSKYCKKYGOGIGITCVYI 273
 DB 202 CHIGFELQYISGRYDCIDINECTMDSHTCSHHANCFTQCSFKCKQYKQNGICRSAL 261
 QY 274 PKYMIPESGPIHVPKNGITLKGDTGNNNWIPDVGSTWMPPKTPYIPPIITNRPSTKPT 333
 DB 262 PENSVK-----EVLNAPGTI-----KDKIKLLAHKNSMKKA 294
 QY 334 R---PTPKPTPIPTPPPPPLTELRTPIPTPTPRPTTGLTIAPAASTPVC----- 383
 DB 295 KIKNVTPEPTRTPT-----KVNLOPFNVE-----IVSRGNSHGKCKGNEEK 338
 QY 384 ---GITVDNRVQ-----TDPQKPRGDVFIPOPSNDLFEIPIERGVSAADDEAKDDPGV 434
 DB 339 MKEGLEDEKREKALKNDIEERSLKGDVFPKVNAGPGLIIVOKKALTSKLEHKDINI 398
 QY 435 LVHSCNFDHGLCGWIREKNDLHWEPI-RDPAGSGYLTYSMAKAPGGAARLVPLGLRLM 493
 DB 399 SV-DCSPNHCIDWKQDRRDDFDNNPADRNALIGYMAVPALAGHKKIDIGIKLLLPDIQ 457
 QY 494 HSGDICTLSPRRKVTGLHSGTIGVYFKKHCAGAAIWRNGCHG--WRQTOITLRCAD-I 549
 DB 458 PQSNFCLLDYRLAGDKVGLRVEVK--NSNNALAWKTTSEDEKWKTKGIQLYQGTDAT 515
 QY 550 KSVVFKGKKRKHGTGPIGLDDVSLKKGHCSE 580
 DB 516 KSIIFPAKCKGKTGTORIAVDCVILVSGICPD 546

RESULT 12
 AA015368
 ID AA015368 standard; Protein: 553 AA.
 AC AA015368;
 XX
 XX 19-SEP-2002 (first entry)
 XX Human EGF motif-containing protein, SHQ ID No 24.
 XX
 XX Human; epidermal growth factor motif; EGF motif; EGFL6;
 KW epidermal growth factor; tissue repair; tissue regeneration;
 KW corneal transplant healing; skin graft; wound healing; cancer; leukaemia;
 KW nervous system disorder; infection; autoimmune disorder; inflammation;
 KW multiple sclerosis; anaemia; periodontal disease; haemophilia;
 KW fertility enhancement.
 XX
 OS Homo sapiens.
 XX
 XX W0200230977-A2.
 XX
 XX 18-APR-2002.
 XX
 XX 15-OCT-2001; 2001W0-US32257.
 XX
 XX 13-OCT-2000; 2000US-0687860.
 XX
 XX (HYPK-) HYSKO INC.
 XX
 XX Asundi V, Ford JE, Drmanac RT, Liu C, Yamasaki V, Yeung G;
 PI Tang TY, Zhang J, Zhou P, Zhou H;
 XX
 XX WPI: 2002-426270/45.
 XX
 XX N-PSDB; AAL43901.
 XX
 PT Novel isolated epidermal growth factor motif polypeptide, termed EGFL6,

PT for treating cancer, nervous system disorders, immune deficiencies,
 PT autoimmune disorders, coagulation disorders and inflammatory conditions
 PS
 XX Claim 28; Page 167-169; 183pp; English.
 XX
 XX The invention comprises the amino acid and coding sequences of human
 CC epidermal growth factor (EGF) motif-containing proteins (EGFL6 proteins).
 CC The DNA and protein sequences of the invention are useful for inhibiting
 CC the proliferation of cells expressing an EGFL6 protein. The DNA and
 CC protein sequences of the invention are useful for stimulating epithelial
 CC tissue growth, for tissue repair and regeneration, corneal transplant
 CC healing, skin graft production and wound healing. The DNA and protein
 CC sequences are useful for treating cancer, leukaemia, nervous system
 CC disorders, autoimmune disorders (e.g. multiple sclerosis),
 CC anaemia, periodontal disease, haemophilia, inflammatory conditions, and
 CC for effecting bodily characteristics and fertility of male or female
 CC subjects. The present amino acid sequence represents a human EGF motif-
 CC containing protein.
 XX
 XX Sequence 553 AA;

Query Match 33.2%; Score 1091.5; DB 23; Length 553;
 Best Local Similarity 37.8%; Pred. No. 1,2e-58;
 Matches 215; Conservative 96; Mismatches 174; Indels 87; Gaps 14;
 QY 34 GICRYGGRIDCCWGNARSWGQCQHPYVLRKHARIKOLKAVGTPRCKHGRITGNPKCK 94
 DB 39 GVCYGTGKLCACGYGHRNSKGVCE-----ATCEPKCKPFCVGVNPKCK 81
 QY 94 CHPGYAGTKTCIQVLNEGLKPRCKXKRCNNTYGSYKCYCLNGYMLMPDSCSSALTCGSA 153
 DB 82 CFCYCTCKTCQVNVNCGMKPRICQRCVNTGHSYKFCPLISCHMLMPDTCVNSRTICAM 141
 QY 154 NCOYGVGVKQIKCOCPSPGQIAPIDRCVCVIVDRCATCRASCPFRPCVNTFGSYICK 213
 DB 142 NCOYSCDETEEGPQCLCPSSGLAPNGRDLIDECASGKVLCPYNRRCVNTFGSYICK 201
 QY 214 CHKGFILMYIGCKYQCHDIDECISIGQYQSSPARCYNVNGSKYCKKYGOGIGITCVYI 273
 DB 202 CHIGFELQYISGRYDCIDINECTMDSHTCSHHANCFTQCSFKCKQYKQNGICRSAL 261
 QY 274 PKYMIPESGPIHVPKNGITLKGDTGNNNWIPDVGSTWMPPKTPYIPPIITNRPSTKPT 333
 DB 262 PENSVK-----EVLNAPGTI-----KDKIKLLAHKNSMKKA 294
 QY 334 R---PTPKPTPIPTPPPPPLTELRTPIPTPTPRPTTGLTIAPAASTPVC----- 383
 DB 295 KIKNVTPEPTRTPT-----KVNLOPFNVE-----IVSRGNSHGKCKGNEEK 338
 QY 384 ---GITVDNRVQ-----TDPQKPRGDVFIPOPSNDLFEIPIERGVSAADDEAKDDPGV 434
 DB 339 MKEGLEDEKREKALKNDIEERSLKGDVFPKVNAGPGLIIVOKKALTSKLEHKDINI 398
 QY 435 LVHSCNFDHGLCGWIREKNDLHWEPI-RDPAGSGYLTYSMAKAPGGAARLVPLGLRLM 493
 DB 399 SV-DCSPNHCIDWKQDRRDDFDNNPADRNALIGYMAVPALAGHKKIDIGIKLLLPDIQ 457
 QY 494 HSGDICTLSPRRKVTGLHSGTIGVYFKKHCAGAAIWRNGCHG--WRQTOITLRCAD-I 549
 DB 458 PQSNFCLLDYRLAGDKVGLRVEVK--NSNNALAWKTTSEDEKWKTKGIQLYQGTAT 515
 QY 550 KSVVFKGKKRKHGTGPIGLDDVSLKKGHCSE 580
 DB 516 KSIIFPAKCKGKTGTORIAVDCVILVSGICPD 546

RESULT 13
 AA015370
 ID AA015370 standard; Protein: 554 AA.
 XX
 XX AC AA015370;
 XX

DT	19-SEP-2002	(first entry)
XX	Human EGF motif-containing protein, SEQ ID NO 30.	
DE	Human; epidermal growth factor motif; EGF motif; EGFL6;	
XX	epithelial tissue growth; tissue repair; tissue regeneration;	
KW	corneal transplant healing; skin graft; wound healing; cancer; leukaemia;	
KW	nervous system disorder; infection; autoimmune disorder; inflammation;	
KW	multiple sclerosis; anaemia; periodontal disease; haemophilia;	
KW	fertility enhancement.	
XX	Homo sapiens.	
OS	Novel isolated epidermal growth factor motif polypeptide, termed EGFL6,	
XX	for treating cancer, nervous system disorders, immune deficiencies,	
PX	autoimmune disorders, coagulation disorders and inflammatory conditions	
PA	(HYSE-) HYSQ INC.	
PI	Asundi V, Ford JE, Drmanac RT, Liu C, Yamasaki V, Yeung G;	
PI	Tang TY, Zhang J, Zhou P, Zhou H;	
XX	WP1; 2002-426270/45.	
DR	N-PSDB; AAL43905.	
DR	Novel isolated epidermal growth factor motif polypeptide, termed EGFL6,	
XX	for treating cancer, nervous system disorders, immune deficiencies,	
PT	autoimmune disorders, coagulation disorders and inflammatory conditions	
PT	-	
XX	Claim 19; Page 176-178; 183pp; English.	
PS	The invention comprises the amino acid and coding sequences of human	
CC	epidermal growth factor (EGF) motif-containing proteins (EGFL6 proteins).	
CC	The DNA and protein sequences of the invention are useful for inhibiting	
CC	the proliferation of cells expressing an EGFL6 protein. The DNA and	
CC	protein sequences of the invention are useful for stimulating epithelial	
CC	tissue growth, for tissue repair and regeneration, corneal transplant	
CC	healing, skin graft production and wound healing. The DNA and protein	
CC	sequences are useful for treating cancer, leukaemia, nervous system	
CC	disorders, infection, autoimmune disorders (e.g. multiple sclerosis),	
CC	anaemia, periodontal diseases, haemophilia, inflammatory conditions, and	
CC	for effecting bodily characteristics and fertility of male or female	
CC	subjects. The present amino acid sequence represents a human EGF motif-	
CC	containing protein.	
XX	Sequence 554 AA;	
SQ	Query Match 33.2%; Score 1091.5; DB 23; Length 554;	
	Best Local Similarity 37.7%; Pred. No. 1.2e-58;	
	Matches 215; Conservative 96; Mismatches 173; Indels 87; Gaps 14;	
QY	34 GICRYGGRIDCCWGAWQSGOCQPFFVLRQRARTRCQLKAYCQPRCKHGECIPNKK 93	
DB	I : I : I : I : I : I : I : I : I : I : I : I : I : I : I : I : I :	
DB	40 GVCHYGTKIACCVCWRNSKVCE-----ATCEPCCKPGEVGVNPKR 82	
QY	94 CHPGYAGTCTIQVLNEGLKPRCKIIRCMNTYGSICYCLNGYLMPDSCSSALTCSMA 153	
DB	I : I : I : I : I : I : I : I : I : I : I : I : I : I : I : I : I :	
DB	83 CFPGYTGTCTSDVDNCGMKPRPCQHRVMTHTGSCFCLSGHMLMPPDATCVNSRTCAMI 142	
QY	154 NCQYGGDVVKGOIRCOCPSPGLQIAPICRTICVDVDECATORASCPRQCVTFTGYICK 213	
DB	I : I : I : I : I : I : I : I : I : I : I : I : I : I : I : I : I :	
DB	143 NCQYSCDETTEGPQCLPESGLRLAPNRDCLDIDEACSKVICPNRRRCVNTFGSYCK 202	
QY	214 CHKFDLMIYIGGKYOCCHDIBECSLGOYCQSFAFCYNVRGYSKCCKEYGGDGILTCVVI 273	
DB	I : I : I : I : I : I : I : I : I : I : I : I : I : I : I : I : I :	
DB	203 CHIGFELOYISCRDYCIDINECTMDSTCSHHANCFTQCSFKCKCKQGYKGHLCASAI 262	
QY	274 PKVMIEFSGIHPKGNSTIKGDITUNNNNIPOVGSTFWPWPKTPYPIPIITINRPTSKPTT 333	

CC sequences are useful for treating cancer, leukaemia, nervous system disorders, infection, autoimmune disorders (e.g. multiple sclerosis), and anaemia, periodontal diseases, haemophilia, inflammatory conditions, and for effecting bodily characteristics and fertility of male or female subjects. The present amino acid sequence represents a human EGF motif-containing protein.

XX Sequence 559 AA;

Query Match 33.2%; Score 1091.5; DB 23; Length 559;
Best Local Similarity 37.7%; Pred. No. 1,30e-58;
Matches 215; Conservative 96; Mismatches 173; Indels 87; Gaps 14;

QY 34 GLCRYGGRIDCCGWARQSGQCQPFYVLRQRIARICQLKAVCPKCKHIGEGIPNKCK 93
DB 45 GVCHYGTGKLACCCGWRNNSKGVCE-----ATCEPGCKFGEVGNPKCK 87

QY 94 CHPGYAGKTCIOVLNPGCLKPRCKHRCMNITYSKYCYCLNGYMLMPDGCSSALTCMA 153
DB 88 CFPGYGTGTCSDVNECGMKPRCQIRCVNTHGYSKCFCLSHMLMPDQATCVNSRTCAMI 147

QY 154 NCQYGCDDVVRGQIRCOCPSPGLQAPDRTCDVDDPCATGRASCPRFCVNTFGSYICK 213
DB 148 NCQYSCDETEEGPQCLCPSSGLGLAPNGRDCIDIDECASGKVICPNRRCVNTEGYYCK 207

QY 214 CHKGFDLMYIGGKYQCHIDIDECISLGQYQCSFARCVNRSYKCKEGYGDGLTCVYL 273
DB 208 CHIGFELOYISGNYDCIDINECTMDSHSTSHHANCNTQCSFKCKQYKGMGLKCSAI 267

QY 274 PKVMIEPSGPIHVPKNGTILKSDTGNNWIPDVGTWMPPTKPIPIITNPTSKPTT 333
DB 268 PENSVK-----EVLAPGTT-----KDRICKLIAHNSMKKA 300

QY 334 R---PTPKPPIPTDTPPPPLPTELKTPPTPTPTPTGLTTTAPAASTPPG----- 383
DB 301 KIKNVPEPTRTTP-----KVNLPFNVE-----IVSRGNSHGKCKNEEK 344

QY 384 ---GIIVDNVQ-----TDQKPRGDVTFIPROPSNDLFEIFIEIRGVASDDAKDPGV 434
DB 345 MKGLIEDKREKREKALANDIPERSIRGIDVFPKVNAGREFGLIIVQRKALTSKLEHDKJNI 404

QY 435 LVHSCNFDHGLCGWIREKNDLWEPI-RDPAGGQYLTYSAAKAPGGKAAARLVPLGRLM 493
DB 405 SV-DCSFNIGICDWKQDREDDFNADRDNAIGFYMAVPALAGHKKDIGRLKLLPDQ 463

QY 494 HSGDGLCLSPHKKVITGLHSCITLOVEFVKHCAHGAALWCRNGCHG--WROVQITL-RCAD-I 549
DB 464 PQSNECLLDFYRLAGDKVGLRVFK--NSNNALWEKTTSEDEKWKTKIQLYQGTDAT 521

QY 550 KSVFKEGKRRRGTGTEIGLDDVSLKKGHCSE 580
DB 522 KSIIFPAERCKGKTGRIVAVGVIIIVSGICPD 552

RESULT 15

AA040942

ID AAM0942 standard; Protein: 573 AA.

XX AC

XX AC

XX XX

XX 22-OCT-2001 (first entry)

XX Human polypeptide SEQ ID NO 5873.

XX Human; neurotropic; immunosuppressant; cytostatic; gene therapy; cancer;
peripheral nervous system; neuropathy; central nervous system; CNS;
Alzheimer's; Parkinson's disease; Huntington's disease; haemostatic;
amyotrophic lateral sclerosis; Shy-Drager Syndrome; chemokine;
chemokine; thrombolytic; drug screening; arthritis; inflammation;
leukaemia.

XX Homo sapiens.

XX

PN W0200153312-A1.
XX 26-JUL-2001.
XX 26-DEC-2000; 2000WO-US34263.
XX 21-JAN-2000; 2000US-0488725.
XX 25-APR-2000; 2000US-052317.
XX 09-JUL-2000; 2000US-0598042.
XX 19-JUL-2000; 2000US-0620312.
XX 03-AUG-2000; 2000US-0653450.
XX 14-SEP-2000; 2000US-0662191.
XX 19-OCT-2000; 2000US-0693036.
XX 29-NOV-2000; 2000US-0727344.
XX (HYSE-) HYSEQ INC.
XX Tang YT, Liu C, Asundi V, Chen R, Ma Y, Qian XR, Ren F, Wang D;
PI Wang J, Wang Z, Wehrman T, Xu C, Xue AJ, Yang Y, Zhang J;
PI Zhao QA, Zhou P, Goodrich R, Dimaane RT;
XX WPI; 2001-442253/47.
XX N-PSDB; AA160098.
XX Novel nucleic acids and polypeptides, useful for treating disorders
XX such as central nervous system injuries -
XX Example 2; SEQ ID NO 5873; 10078pp; English.
XX The invention relates to human nucleic acids (AA157798-AA163469) and
XX the encoded polypeptides (AA138642-AA142213) with neurotropic,
XX immunosuppressant and cytostatic activity. The polynucleotides are useful
XX in gene therapy. A composition containing a polypeptide or polynucleotide
XX of the invention may be used to treat diseases of the peripheral nervous
XX system, such as peripheral nervous injuries, peripheral neuropathy and
XX localised neuropathies and central nervous system diseases, such as
XX Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic
XX lateral sclerosis, and Shy-Drager Syndrome. Other uses include the
XX utilisation of the activities such as: immune system suppression,
XX activation/inhibition activity, chemotactic/chemokinetic activity, haemostatic
XX and thrombolytic activity, cancer diagnosis and therapy, drug screening,
XX assays for receptor activity, arthritis and inflammation, leukaemia and
XX C.N.S disorders.
XX Note: The sequence data for this patent did not form part of the printed
XX specification.
XX Sequence 573 AA;
Query Match 33.0%; Score 1084; DB 22; Length 574;
Best Local Similarity 37.8%; Pred. No. 3.7e-58;
Matches 219; Conservative 99; Mismatches 161; Indels 100; Gaps 18;
QY 34 GLCRYGGRIDCCGWARQSGQCQPFYVLRQRIARICQLKAVCPKCKHIGEGIPNKCK 94
DB 56 GVCHYGTGKLACCCGWRNNSKGVCE-----ATCEPGCKFGEVGNPKCK 98

QY 94 CHPGYAGKTCIOVLNPGCLKPRCKHRCMNITYSKYCYCLNGYMLMPDGCSSALTCMA 153
DB 99 CFPGYGTGTCSDVNECGMKPRCQIRCVNTHGYSKCFCLSHMLMPDQATCVNSRTCAMI 158

QY 154 NCQYGCDDVVRGQIRCOCPSPGLQAPDRTCDVDDPCATGRASCPRFCVNTFGSYICK 213
DB 159 NCQYSCDETEEGPQCLCPSSGLGLAPNGRDCIDIDECASGKVICPNRRCVNTEGYYCK 218

QY 214 CHKGFDLMYIGGKYQCHIDIDECISLGQYQCSFARCVNRSYKCKEGYGDGLTCVYL 273
DB 219 CHIGFELOYISGNYDCIDINECTMDSHSTSHHANCNTQCSFKCKQYKGMGLKCSAI 278

QY 274 PKVMIEPSGPIHVPKNGTILKSDTGNNWIPDVGTWMPPTKPIPIITNPTSKPTT 333
DB 279 PENSVK-----EVLAPGTT-----KDRICKLIAHNSMKKA 311

QY 334 R---PTPKPPIPTDTPPPPLPTELKTPPTPTPTPTGLTTTAPAASTPPG----- 483

```

Db 312 KIKNVTPETRTPT-----KVNLQPNYER-----IVSRGGSNHCCKKCNEEK 355
QY 384 ----GITVDNRVOT-----DPQKP-RGDVFIPRQFSNDLFEIFEIER-GVSADDEAKDDP 432
Db 356 MKEGLFDEKREKALKDXHRRERPFPGDVFFPKVNFAGEFGI.II.VORKALTSKLEKKAADI 415
QY 433 GVLVHSCNFDHGLCGWIREKDNDLHWEPI-RDPAGCQYLVSAKAPG-----GKAARL 485
Db 416 NISV-DCSFNHGICDWKQDREDDFDWNPADRONAIGFYNAV-----PGLWQGHKKDIGRL 469
QY 486 VLPFLCHLHMSGDICIJSFRHKVTGLHSGTIIQVFVRKHGAHCAALWGRNGCHG--WRQTQIT 543
Db 470 KIJLLPDLQPSNFCILIFDYRLAGDKVGLRVFVK--NSNNALAWKTTSEDEKWKTKIQ 527
QY 544 L-RGAD-IKSVVFKGKRRGHTGETGLDDVSLKKGHCSE 580
Db 528 LYQGTATKSIITFEAERGKKTGETAVDGVLIIVSGICPD 566
```

Search completed: April 23, 2003, 13:01:06
Job time : 43 secs

10